Edgen Stock·Oct 31 2025, 09:15Back
Takeda Pharmaceuticals Reports Mixed Q2 FY2025 Results Amidst Vyvanse Erosion and Revised Full-Year Outlook
Edgen Stock·Oct 31 2025, 09:15
[1] Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript (https://seekingalpha.com/article/4835369-take ...)[2] Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression - BioSpace (https://www.biospace.com/article/takeda-annou ...)[3] Takeda's Entyvio holds onto IBD market share despite threat from AbbVie's Skyrizi - Fierce Pharma (https://www.fiercepharma.com/pharma/takedas-e ...)
